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Enalapril maleate, the oldest and most widely distributed ACEI, and alacepril, the newest and antioxidant ACEI, were compared in
the point of cardioprotective eﬀect for Dahl salt-sensitive rat. In order to evaluate the correlation between the three factors, cardiac
ﬁbrosis and blood pressure/oxidative-stress marker (tissue TBARS), index of correlation was calculated. The results showed a
signiﬁcantdiﬀerenceincardiacﬁbrosisbetweenhigh-dosealacepril(30mg/kg/day,groupH)andenalaprilmaleate(10mg/kg/day,
group E). There was signiﬁcant correlation between cardiac ﬁbrosis and oxidative-stress marker, although there was no correlation
between cardiac ﬁbrosis and blood pressure. Fibrosis was more inﬂuenced by oxidative stress not by blood pressure, we should not
select ACEI only by blood pressure-lowering eﬀect and should more consider cardioprotective eﬀects of ACEI.
1.Introduction
Heart failure is deﬁned as a syndrome that demonstrates a
systolicdysfunction,diastolicdysfunction,orboth.Thereare
many mechanisms by which heart failure can be induced.
However, cardiac remodeling and sequential ﬁbrosis of
cardiac muscle seems to contribute equally to cardiac failure.
Although many factors are referred to as causative agents
in cardiac remodeling, the renin-angiotensin system (RAS),
sympatheticnervesystem,andreactiveoxygenspecies(ROS)
are considered the major factors that intricately interact with
each another. Because angiotensin II (Ang II) is generated
by the RAS and induces the activation of sympathetic nerve
system and augmentation of ROS, regulation of the RAS is
recognized as an important measure for preventing ﬁbrosis
of cardiac muscle.
Two types of RAS, circulating RAS and cardiac RAS,
which act in diﬀerent ways have been reported [1–6].
Circulating RAS is activated in response to decreased cardiac
output where it increases blood pressure by constricting the
peripheral vessels mainly via sodium retention. Cardiac RAS
directlystimulatescardiomyocytehypertrophyandﬁbroblast
proliferation, which leads to left ventricular hypertrophy,
diastolic and systolic dysfunction, arrhythmia, heart failure,
and, ultimately, cardiac cell death. To maintain the cardiac
function, inhibition of cardiac RAS seems important, and
many types of angiotensin-converting enzyme inhibitors
(ACEIs) are used for this purpose [7].
Various types of ACEIs with very similar basic vasode-
pressive eﬀects are available; however, they diﬀer slightly in
their pharmacokinetics. To stabilize the therapeutic eﬀect
and minimize the adverse eﬀects, the currently available
ACEIs are in the form of prodrugs and need to be converted
into an active form in the body before they take eﬀect. In
addition, some ACEIs may act more directly on ACE in
tissues than on ACE in the circulating blood [8]. Currently,
ﬁvesuchACEIsarecommerciallyavailableforveterinaryuse;
however,thesedrugshavenotbeenfullyinvestigatedthrough
comparative studies to determine which of these drugs is
more eﬀective and advantageous in treating heart failure.2 Veterinary Medicine International
For example, although alacepril is a long-acting, sulfhydryl-
containing ACEI, very little information is available regard-
ing its cardioprotective eﬀects [9]. In the present study,
we evaluated the cardioprotective eﬀects of alacepril and
compared the eﬀects with another ACEI, enalapril, which is
widely used in veterinary medicine.
2.MaterialsandMethods
The experimental procedures were approved by the Insti-
tutional Animal Care and Use Committee of the Tokyo
University of Agriculture and Technology. Three-week-old
Dahl salt-sensitive rats (DS rats; Saitama Experimental
Animals Supply, Saitama, Japan) were fed a low-salt (0.3%
NaCl) diet (BP 168.8 ± 52mmHg), and by 7 weeks of age,
they were switched to a high-salt (8% NaCl) diet. They were
then divided into four subgroups that received a low dose of
alacepril (10mg/kg/day, Group L), a high dose of alacepril
(30mg/kg/day, Group H), enalapril (10mg/kg/day, Group
E), and placebo (5% gum Arabic solution, Group P). From
7 weeks of age, noninvasive blood pressure measurements
were obtained every 2 weeks using a tail-cuﬀ method
(MK-2000, Muromachi Kikai Co., Ltd., Tokyo, Japan).
Echocardiographic studies were performed using a phased
arraysectorscanner(SSD-5000,Aloka,Tokyo,Japan).Under
general anesthesia with intraperitoneal administration of
ketamine hydrochloride (60mg/kg) and xylazine hydrochlo-
ride (5mg/kg), a right parasternal short-axis image was
obtained. In the papillary muscles, the size of the diastolic
thickness of the interventricular septum (IVSd, mm), the
diastolic thickness of the interventricular septum (IVSs,
mm)), the diastolic thickness of the left-ventricular posterior
wall (LVPWd, mm), the systolic thickness of the left-
ventricular posterior wall (LVPWs, mm), the left-ventricular
internal dimension at end diastole (LVIDd, mm), and the
left-ventricular internal dimension at end systole (LVIDs,
mm) were measured with M-mode measurement, and the
fractional shortening (%FS) was calculated from LVIDs and
LVIDd. A left parasternal apical four-chamber view was
then obtained to record mitral inﬂow. The E and A peaks
were measured, and the A/E ratio was calculated. Each
echocardiographic measurement was repeated three times,
and their average value was used for assessment.
At 19 weeks of age, the rats received a lethal injection
of sodium pentobarbital. Blood samples were collected
from the vena cava, after which a midline thoracotomy
was performed and the heart was removed and cut cross-
sectionally at the papillary muscle. The apical region of the
heart was used for the assay of oxidative stress, and the basal
region for the measurement of cardiac ﬁbrosis. Both blood
and cardiac samples were immediately frozen and stored at
−80◦C until the measurements were obtained.
Urine 8-hydroxy-2 deoxyguanosine (8-OHdG) and
plasma and tissue thiobarbituric acid reactive substances
(TBARS) were used as indexes of lipid peroxidation and
oxidative stress. 8-OHdG levels were determined by the
method previously reported using commercial assay kit
(Highly sensitive ELISA kit for 8-OHdG, JaICA, Hukuroi,
Japan), applicable to samples from human, mouse, rat,
rabbit, dog, cattle, and horse [10]. After incubation and
washing, an anti-mouse secondary antibody conjugated
to horseradish peroxidase was used to determine the
bound monoclonal antibody. The color yield was directly
proportional to the analyte concentration. Data reduction
was conducted by four-parameter logistic curve ﬁt. TBARS
levels were determined by the method previously reported
using commercial assay kit (TBARS Assay Kit, Cayman
Chemical Company, Michigan, USA) [11]. Brieﬂy, serum
samples and homogenized tissue samples were incubated
with TBA-working solution and the colored complex was
determined at 532nm, and TBARS concentration was then
calculated using a calibration curve constructed from 1,1,3,3
tetraethoxypropane. Urine 8-OHdG and plasma/tissue
TBARS were expressed in concentrations (ng/mL, nmol/mL
and nmol/mg protein, resp.).
Left ventricular histological examination was conducted
to quantify the cardiac ﬁbrosis. The ventricles were paraﬃn-
embedded and cut into thin sections (thickness: 3µm) in
the usual manner. They were then stained with hematoxylin-
eosin and picrosirius red stain. The collagen density per-
centage was determined in the left ventricle. Each region
was assessed following staining with picrosirius red in 10
random ﬁelds with a magniﬁcation of ×200. The collagen
density percentage was calculated using a computerized
morphometry system (Mac Scope Ver 2.69.1, Mitani Co.,
Fukui, Japan), and the sum of all the areas stained positive
for sirius red was divided by the sum of all myocardial areas
for each individual rat.
Statistical analysis was conducted using commercial
software (PRISM 5 for Mac, GraphPad software Inc., CA,
USA). Results are expressed as mean ± SD. Diﬀerences
at speciﬁc stages between groups were assessed using one-
way ANOVA and Bonferroni’s multiple comparison test. A
probability value of P<0.05 was considered statistically
signiﬁcant.
3. Results
A total of 40 DS rats (10 rats in each group) were used in
the present study. The mean blood pressure before ACEI
administration was 136.9 ± 4.2mmHg, and a signiﬁcant
increase were observed in each group at 19 weeks of
age (Group P: 255.6 ± 23.9mmHg; Group L: 242.8 ±
17.2mmHg;GroupH:224.9±20.2mmHg;GroupE:236.9±
38.4mmHg, Figure 1). Group H showed suppressive eﬀect,
although there was no signiﬁcant diﬀerence between the
groups. There was no signiﬁcant diﬀerence in the heart rates
between the groups.
Detailed data from the echocardiographic studies are
summarized in Table 1. At 19 weeks of age, signiﬁcant
decreases in IVSd, IVSs, and LVPWd were noted in Group E;
however, there were no signiﬁcant changes in these ﬁndings
in Groups L, H, and P. In addition, no statistically signiﬁcant
diﬀerence was observed among the ACEI administration
groups (Groups L, H, and E). Also, no signiﬁcant diﬀerence
in %FS was noted before and after ACEI administration.Veterinary Medicine International 3
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Figure 1: The mean blood pressure (mmHg), plasma TBARS (nmol/mL), tissue TBARS (nmol/mg protein), and cardiac ﬁbrosis in LV (%)
after ACEI administration. Cardiac ﬁbrosis in LV was decreased in Group H and increased in Group E, so that there was a signiﬁcant
diﬀerence between Group H and Group E.
Table 1: Echocardiographic data in 19 weeks. Detailed data from the echocardiographic studies. No statistically signiﬁcant diﬀerence was
observed among the ACEI administration groups in IVSd, IVSs, LVPWd, and %FS.
IVSs (mm) LVIDs (mm) LVPWs (mm) IVSd (mm) LVIDd (mm) LVPWd (mm) FS (%) E/A
Group P 0.73 ±0.07 0.48 ±0.07 0.31 ±0.02 0.28 ±0.03 0.48 ±0.07 0.26 ±0.01 33.6 ±4.20 .84 ± 0.13
Group L 0.76 ±0.10 0.53 ±0.05 0.27 ±0.05 0.25 ±0.05 0.53 ±0.09 0.25 ±0.04 29.6 ±4.90 .68 ± 0.07
Group H 0.83 ±0.10 0.54 ±0.05 0.28 ±0.04 0.24 ±0.03 0.54 ±0.11 0.23 ±0.03 35.1 ±7.10 .83 ± 0.18
Group E 0.82 ±0.04∗ 0.55 ±0.03 0.27 ±0.02 0.24 ±0.02∗ 0.55 ±0.09 0.22 ±0.03∗ 32.8 ±8.40 .66 ± 0.35
Mean ± SD, ∗means signiﬁcant decrease compared with Group P.
The detailed data relating to urine 8-OHdG, plasma, and
tissue TBARS and ﬁbrosis are summarized in Table 2.T h e r e
were no diﬀerences between the groups except for cardiac
ﬁbrosis. On left ventricular histological examination, cardiac
ﬁbrosis was lowest in Group H (2.74 ± 0.66%), and there
were signiﬁcant diﬀerences between Group E (P = 0.014).
There were no signiﬁcant diﬀerences between Group E and
Group P.
The coeﬃcient of correlation between cardiac ﬁbrosis
and blood pressure (mmHg)/tissue TBARS (nmol/mg pro-
tein) is shown in Figure 2. Tissue TBARS in Groups P and
L were not signiﬁcantly correlated with cardiac ﬁbrosis in
the left ventricle and blood pressure (P = 0.76 and P =
0.95, r = 0.01 and r = 0.001, resp., for cardiac ﬁbrosis
and P = 0.92 and P = 0.52, r = 0.001 and r =
0.07, resp., for blood pressure). Tissue TBARS in Groups
H and E were signiﬁcantly correlated with cardiac ﬁbrosis
in the left ventricle (P = 0.04 and P = 0.02, r = 0.59,
and r = 0.51, resp.), whereas there was no signiﬁcant
correlation between cardiac ﬁbrosis and blood pressure
(P = 0.72 and P = 0.09, r = 0.02, and r = 0.31,
resp.).4 Veterinary Medicine International
Table 2: Urine 8-OHdG, plasma, tissue TBARS, and ﬁbrosis. The detailed data relating to urine 8-OHdG, plasma, and tissue TBARS and
ﬁbrosis. Cardiac ﬁbrosis was lowest in Group H, and there were signiﬁcant diﬀerences between Group E (P = 0.014).
Plasma TBARS
(nmol/mL)
Urine 8-OhdG
(ng/mL)
Tissue TBARS (value per
protein, nmol/mg protein)
Tissue TBARS (value per
weight of tissue, nmol/g)
Cardiac ﬁbrosis
(%)
Group P 5.6 ±2.55 .3 ±0.91 .0 ±0.66 1 .5 ±35.32 .971 ±0.7517
Group L 6.5 ±4.05 .6 ±1.11 .4 ±0.58 2 .1 ±30.53 .065 ±0.5602
Group H 7.2 ±3.55 .8 ±1.20 .8 ±0.54 6 .4 ±30.22 .744 ±0.6649∗
Group E 6.6 ±3.06 .2 ±2.21 .3 ±0.88 0 .9 ±48.13 .390 ±0.5650
Mean ± SD, ∗means signiﬁcant decrease compared with Group E.
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Figure 2: The coeﬃcient of correlation between cardiac ﬁbrosis and blood pressure (mmHg)/tissue TBARS (nmol/mg protein). Tissue
TBARS in Groups H and E were signiﬁcantly correlated with cardiac ﬁbrosis in the left ventricle, whereas there was no signiﬁcant correlation
between cardiac ﬁbrosis and blood pressure.
4. Discussion
DS rat have been reported to show steep elevation in
blood pressure depending on the amount of salt intake
[12, 13]. Elevation in blood pressure and progressive left
ventricular hypertrophy have been observed at 4 to 5 weeks,
resulting in overt diastolic heart failure at approximately 19
weeks [14]. In the present study, ACEI was administered
from weeks 7 to 19, a timeframe that was anticipated
to encompass the early stage through the end stage of
hypertensive heart failure. However, high blood pressure
occurred by high-salt food showed large variation and there
are some diﬃculty in comparing drug eﬀect between each
group.
No diﬀerences in blood pressure were observed between
the groups. At 19 weeks of age, ACEI administration began
to decrease the blood pressure, especially in Group H.
The decrease in blood pressure observed in the high-dose
alacepril group could have been due to the drug potency;
alternately, an antiadrenergic or antioxidant eﬀect, which
only alacepril possesses, might have been acting synergisti-
cally to promote the hypotensive eﬀect.
To study the antiadrenergic eﬀect of alacepril, cardiac
rate was monitored. There were no signiﬁcant diﬀerences
betweengroups,andadirectantiadrenergiceﬀectofalacepril
was not conﬁrmed. The cardiac rate of the conscious DS
rats is about 500 beats/min, and this rate might have
been elevated because of the stress of the blood pressure
measurementinthepresentstudy.Assessmentofcardiacrate
therefore seems unsatisfactory as a method of estimating the
antiadrenergic eﬀect; another method, such as measurement
of blood norepinephrine concentration, might provide a
more accurate alternative.
Antioxidant eﬀect was estimated by three parameters:
8-OHdG in blood plasma and urine, and tissue TBARS
in heart muscle. 8-OHdG is released into cytoplasm when
deoxyguanine is attacked by oxidative damage. Released 8-
OHdG is not metabolized; it circulates in the blood and
is then excreted as a ﬁltrate in the urine [15]. Because
8-OHdG is easily measured in blood plasma and urine,
its presence was expected to be a marker of oxidative
stress available for repeat measurement. However, 8-OHdG
showed no diﬀerences between the groups. In fact, 8-OHdG
has dynamic physiological variation, especially in urine, andVeterinary Medicine International 5
does not reﬂect the condition of the heart. Therefore, it
cannot be considered as an index for determining the cardiac
eﬀects of ACEIs. On the other hand, tissue TBARS in Group
H showed a signiﬁcant decrease compared with Group E.
TBARS are generated when the phospholipids in the cell
membrane are oxidized by lipoperoxide; therefore, it is used
as a parameter of oxidative damage in cell membrane [16].
However, TBARS also can be generated in other ways. For
accuratemeasurement,weshouldmeasuresamplesonalike-
for-like basis and compare the results in relative ways [17].
Because the samples for TBARS in the present study were
limited to tissues obtained from the heart base of DS rats,
and the sample collection and measurement were conducted
using the same conditions, the results of TBARS indicated
the relative level of free radicals. The decrease in free radicals
observed in Group H compared with Group E was caused
by the antioxidant eﬀect of the sulfhydryl group present in
desacetylalacepril and captopril, along with the pressure load
reduction, which contributed to the reduction in oxidant
stress. Through these mechanisms, high dose of alacepril
could reduce the production of ROS in cardiac muscle tissue
and provide a cardioprotective eﬀect.
Measurement of cardiac ﬁbrosis in the left ventricle
represents the amount of cardiac remodeling of the heart
exposed to high blood pressure for 12 weeks. Although
decreased ROS levels were observed in Group H, no
signiﬁcant decrease in cardiac ﬁbrosis nor blood pressure
was observed between Group P. One reason for this result
was that Group P showed high dispersion of the drug, which
might have been related to dispersion in salt-sensibility,
pressure overload, and reactivity to the ROS. In addition, the
rate of cardiac ﬁbrosis was low in each group, and therefore
it was not considered as a signiﬁcant diﬀerence except for
between Group H and Group E. From our previous study,
we had thought that 12 weeks would be suﬃcient to induce
cardiac failure; however, a longer observation period might
be necessary [18]. Cardiac ﬁbrosis in the left ventricle
showed signiﬁcant diﬀerences between Groups H and E.
However, there were no signiﬁcant diﬀerences against Group
P, and therefore we were unable to determine whether the
result was derived from the increased ﬁbrosis in Group E
or from the decreased ﬁbrosis in Group H. To interrelate
cardiac ﬁbrosis with other factors at an individual level,
the coeﬃcient of correlation against blood pressure and
tissue TBARS was calculated. Strong correlations were noted
between cardiac ﬁbrosis and tissue TBARS in Groups E and
H; however, there were no signiﬁcant correlations between
cardiac ﬁbrosis and blood pressure or between cardiac
ﬁbrosis and tissue TBARS in Groups P and L. Because
cardiac ﬁbrosis showed no signiﬁcant negative correlation
with blood pressure, there were assumed to be no causal
association between cardiac ﬁbrosis and blood pressure in
thespontaneouslyhypertensiverats.Thecorrelationbetween
cardiac ﬁbrosis and tissue TBARS showed large variations
between the groups. Oxidative stress has been implicated
in the pathogenesis of Ang-II-related hypertension and
regulates the renewal or senescence of stem and progenitor
cells [19]. Because TBARS can also be inhibited by ACEIs or
angiotensin receptor blockers through the antiangiotensin
II mechanism independently of blood pressure reduction
[20–22], the anti-oxidative mechanism of the sulfhydryl
group possessed by desacetylalacepril was very diﬃcult to
estimate. Although more detailed studies will be needed to
clarify the precise antiﬁbrotic mechanism of alacepril, it was
suggested that cardiac ﬁbrosis was inﬂuenced more strongly
by ROS than by blood pressure under ACEI administration.
Cardiac hyperplasia was observed at the posterior wall
of the left ventricle and the interventricular septum on
echocardiography at 19 weeks of age. Pressure overload was
the main reason for the hyperplasia, and ACEIs showed a
suppressive eﬀect on its development. Signiﬁcant diﬀerences
were observed between Groups P and E, but not between
the groups given ACEIs. It has been reported that the
rennin system is not aﬀected by salt-induced hypertension
in the DS rat and the sympathetic nervous system is more
involvedinthismodel[23].Systolicfunctionwasmaintained
through the drug administration schedule because the %FS
did not alter during this period. Based on the ﬁndings
relating to cardiac ﬁbrosis, no remodeling appears to have
occurred, which causes serious systolic dysfunction. Because
the posterior wall of the left ventricle of the DS rat is only
2mm thick and the heart rate was as rapid as 200 beats/min,
it was diﬃcult to judge the extent of cardiac ﬁbrosis from the
results of echocardiography alone.
5. Conclusions
The present study reported relatively low levels of cardiac
ﬁbrosis in DS rats used in the present study, and this study
modelseemedtobeinappropriatefortheevaluationofACEI
for suppression of ﬁbrosis. However, individual analysis of
the rate of ﬁbrosis, ROS, and blood pressure enabled us
to demonstrate the relationship between these factors. The
results showed the importance of ROS in heart muscle, and
suggest that we should pay more attention to this factor
when we use ACEIs to treat patients with heart failure.
In the present study, we used the pressure overload model
to evaluate the direct sympathoinhibitory action and free
radical scavenging eﬀect more clearly; however, the general
indication for use of alacepril in veterinary medicine is
volumeoverloadsuchasmitralregurgitation.Weshouldalso
evaluatetheeﬀectofalaceprilusingavolumeoverloadmodel
from the perspective of its free radical scavenging eﬀect.
Abbreviations
ACEI: Angiotensin-converting enzyme inhibitors
RAS: Renin-angiotensin system
ROS: Reactive oxygen species
8-OHdG: 8-hydroxy-2 deoxyguanosine
TBARS: Thiobarbituric acid reactive substances
IVSd, mm: The diastolic thickness of the
interventricular septum
IVSs, mm: The systolic thickness of the
interventricular septum
LVPWd, mm: The diastolic thickness of the
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LVPWs, mm: The systolic thickness of the
left-ventricular posterior wall
LVIDd, mm: The left-ventricular internal dimension at
end diastole
LVIDs, mm: The left-ventricular internal dimension at
end systole
%FS: The fractional shortening.
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